The company uses a proprietary technology for non-invasive intranasal delivery, and is focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases, as well as immunotherapeutics for the prevention and treatment of infectious disease. Altimmune's lead product candidate, pemvidutide, is being developed for the treatment of obesity and NASH, while HepTcell is being developed to achieve a functional cure for chronic hepatitis B virus. The company's influenza vaccine candidate, NasoVAX, stimulates multiple arms of the immune system and is easier to administer through an intranasal spray. Altimmune is also developing two next-generation anthrax vaccine candidates, NasoShield and SparVax-L, which are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.